Introduction
Imaging and physiological studies have shown that asthma patients may be subject to morphometric and functional changes in the small airways, including the acinar airways [1] . Clinical studies have also shown that in asthma patients, ventilation heterogeneity in the peripheral lung zone correlates with asthma control [2] . Very recently, asthma severity has been shown to correlate with increased acinar ventilation heterogeneity [3] . In patients with a marked baseline abnormality in acinar ventilation heterogeneity, this heterogeneity could be partly reduced by small particle steroid aerosols, while patients with normal baseline acinar heterogeneity were unaffected by steroid particle size [4] . In those patients displaying reversibility of acinar heterogeneity, reversibility was of the order of 20%, with considerable residual abnormality persisting. Since no inflammatory markers were obtained in that study, it was impossible to know whether this residual small airway dysfunction was inflammatory in origin. Other studies using alveolar nitric oxide as an outcome parameter, have observed decreases in alveolar nitric oxide following small particle steroid formulations in relatively mild asthma or with systemic treatment in mild-to-moderate refractory asthma [5] . Alveolar nitric oxide has also been shown to be weakly associated with acinar ventilation heterogeneity, at least in asthma patients on a maintenance treatment exceeding 500 mg BDP equivalent per day [6] .
In the present work we aimed to promote reversibility of acinar airway function in asthma patients with abnormal acinar ventilation heterogeneity at baseline, despite being clinically stable. The way to achieve this was to screen asthma patients for increased baseline acinar ventilation heterogeneity, and have them switched from a standard inhaled corticosteroid (iCS) to a fine particle iCS formulation. While ventilation heterogeneity in the acinar airways was the primary outcome measure, we also examined several other physiological indices reflecting other aspects of small airways function, such as alveolar nitric oxide, frequency dependence of resistance and plethysmographic volumes [7] . All measurements were done at baseline, following 3 weeks of reference medication, 6 weeks after introducing study medication, and after another 6 weeks of study medication.
In order to specifically study the inflammatory component of acinar ventilation heterogeneity, we isolated the corticosteroid from the long acting beta-agonist (LABA) by administering the inhaled steroid, either in standard or fine particle formulation, separately from the LABA. Given the commercial availability of inhaler devices and the doubledummy design, the iCS and LABA inhalation by separate devices required a considerable number of puffs. To avoid the risk of non-compliance or error due to the number of puffs, the present study included only asthma patients on 800 mg equivalent BUD dose or less per day.
Materials and methods

Study subjects
The study protocol was approved by the local ethics committee and registered in the ISCRTN clinical trials database (ISCRTN17195095). Recruitment took place in the respiratory outpatient clinic of a university hospital among nonsmokers with physician-documented asthma. In order to be eligible for a screening visit, asthma patients had not experienced any asthma exacerbations in the previous 6 months. They were clinically stable under a maintenance ICS dose of 800 mg BUD equivalent per day and had not had any change in medication during the previous 3 months. After giving their informed consent, asthma patients were screened for acinar ventilation heterogeneity by means of the Multiple Breath nitrogen Washout (MBW) test and included in the study only if Sacin, the MBW parameter reflecting acinar ventilation heterogeneity and the primary outcome variable, exceeded 0.12 L À1 . This cutoff value, as well as the number of patients to be recruited for this study was based on our previous study [4] . We aimed to recruit 35 patients in order to ensure full data sets on all visits on at least 15 patients in each treatment arm.
Study design
This study was conducted in a double blind fashion and because of differences in commercially available inhalers devices, a double dummy design had to be applied, inflating the number of inhalations needed per day. After inclusion and careful instruction on the use of the different inhalers, a 3-week run in period started, during which all patients were treated with the reference medication (DPI-BUD; Turbohaler) at a dose equipotent to their maintenance iCS dose, based on equivalence tables [8] . At the second visit, participants were randomized to either the fine particle iCS treatment group receiving an equipotent dose of HFA-BDP [8] or to the control group remaining on the reference DPI-BUD treatment. For those patients previously treated with a long acting b 2 agonist (LABA) in combination with iCS, LABA treatment was continued at the same dosage with separate inhalers throughout the study. After randomization, study visits for complete lung function testing were scheduled at baseline, 6 and 12 weeks later ( Fig. 1) . At each study visit, patients completed an Asthma Control Test (ACT) and after a baseline spirometry, bronchodilation was induced by 400 mg salbutamol (inhaled with Volumatic spacer). Ten minutes later, the following sequence of lung function tests were initiated: exhaled NO measurements, spirometry, body plethysmography, MBW testing, and impulse oscillometry.
Methods
Lung function measurements were obtained by means of standardized equipment (Vmax20C, CardinalHealth â , Bilthoven, The Netherlands) according to recommendations [9] or by validated custom-built equipment previously described for exhaled NO measurements [6] , impulse oscillometry [10] and MBW testing [11] in our laboratory. For spirometry and plethymography the 1993 ERS reference values [9] were used. For the MBW parameters (with the primary outcome variable Sacin), a recent report with reference values in the age range 25e65years [11] could now be used to obtain predicted values.
Parameters included
(1) exhaled NO: by measuring exhaled NO at expiratory flows between 100 and 350 ml s À1 , and using the regression method of Pietropaoli [12] and the back diffusion correction method by Kerckx et al. [13] , we obtain bronchial NO production [J'aw(pl/s)] and alveolar NO concentration (Calv) with or without back diffusion correction; exhaled NO measured at 50 ml s À1 (FENO 50 ) was also recorded; 
Statistical analysis
Two-way ANOVA (within: visit; between: group) was performed to detect differences in ACT scores and all lung function parameters between groups and across visits using Statistica 5.1 (StatSoft, Tulsa, OK). Significance was accepted at p Z 0.05.
Results
Sixty-six patients had to be screened to include 35 eligible patients with baseline Sacin above the cut-off; of these 35 patients, 31 (15 male, 16 female) completed the study. Three patients had dropped out because of an exacerbation requiring oral corticosteroids (2 from the control arm, and 1 from the fine particle iCS arm) and a fourth patient because of technical failure during the baseline visit. The final study population consisted of 31 patients, with an average age of 52 AE 17(SD) years, an average post bronchodilator FEV 1 84 AE 17(SD) %predicted and Sacin of 165 AE 69(SD) %pre-dicted. Twenty six out of 31 patients were atopic. Sixteen patients were randomized to the control group (BUD-DPI) and 15 to the study group (BDP-HFA). There were no baseline differences in anthropometric data, maintenance iCS dose and ACT score between both groups ( Table 1) . None of the lung function parameters, except for FEV 1 /FVC (p Z 0.04), showed any baseline difference between both treatment arms. Six and 12 weeks after randomization, no significant changes in any index of large or small airways function had occurred in either study group (Tables 1e3) and asthma control was maintained in both groups (Table 1 ). In particular, with 15 patients in the fine particle treatment and the measurement variability obtained here, this study was powered (a Z 0.05; b Z 0.10) to detect a reversibility of acinar abnormality of 25%predicted. This is approximately half of the reversibility required to obtain normal Sacin values in the patient population under study, considering that baseline Sacin was approximately 150% pred in the fine particle iCS group.
By design, Sacin was elevated at baseline (Table 1) . While not being primary variables, the impulse oscillometry indices also reflect some degree of structural abnormality at baseline. For instance, the median R 5 value for the entire group (0.41 kPa L À1 s) was close to the recently reported ULN [14] applied to our age group (0.43 kPa L À1 s); the corresponding predicted median value was 0.25 kPa L À1 s. Another parameter thought to primarily reflect the smaller airways, i.e., the frequency dependence of resistance (R 5 eR 25 ), fell within the normal range in our study group, but was almost double the predicted median value. Indeed, our median value of R 5 eR 25 for the entire group at baseline was 0.061 kPa L À1 s, compared to the predicted median (0.035 kPa L À1 s) and ULN (0.115 kPa L À1 s) reported for R 5 eR 20 (R 20 and R 25 are almost indistinguishable). Finally, the median X 5 for our study group (À0.10 kPa L À1 s) was relatively close to the predicted median value (À0.083 kPa L À1 s) with LLN Z À0.143 kPa L À1 s. Taken together, these impulse oscillometry indices do indicate a mild degree of peripheral structural alterations at baseline, consistent with MBW indices Sacin and Scond. The fact that neither of these indices show any significant change after treatment, confirms the absence of structural change with treatment at any level of the airway tree.
Besides the mechanical structural abnormalities observed by MBW and IOS indices, the inflammatory parameters, i.e., bronchial NO production and alveolar NO concentration, were entirely normal in either study group Figure 1 Schematic representation of the study schedule. After a 3 week run-in period on DPI-BUD, patients are randomized to either the study group (HFA-DBP) or to the control group (DPI-BUD) for 12 weeks.
( Table 2 ) and did not change with treatment. In particular, the values for bronchial NO production and alveolar NO concentration obtained here fall within the ranges of normal obtained in a recent compilation [5] while the FENO 50 values are well below the cut-off reported for identifying patients with eosinophilic airway inflammation [15] .
Discussion
In this group of asthma patients with an average post bronchodilator FEV 1 of 84%pred, and with a maintenance dose of maximum 800 mg BUD equivalent, the baseline abnormality of acinar ventilation heterogeneity could not be significantly improved by reducing inhaled steroid particle size. The patients selected for this study according to their baseline acinar abnormality were not severe asthmatics, as their asthma was controlled under a low or medium dose of inhaled steroids [8] . We therefore expected that a significant reversibility to normal could be achievable with a small particle iCS. Considering the power analyses performed for this study, any clinically meaningful reversibility of acinar ventilation heterogeneity towards normality should have been detected. Therefore we must conclude that for the asthma patients under study here in their best possible state (after bronchodilation), no improvement of their abnormal acinar ventilation heterogeneity could be obtained by changing steroid particle size only. This negative study with respect to the primary outcome variable Sacin was confirmed by various other parameters (displayed across Tables 1e3) that may not be directly related, but that also potentially reflect changes in the most peripheral air spaces [7] . None of the alternative small airway parameters such as FEF 25e75, RV/TLC, R 5 eR 25, alveolar NO measured here indicated any marked improvement or deterioration of peripheral lung function when switching to a fine particle inhaled steroid formulation. Several of these indices of small airway function intrinsically suffer from a lack of specificity, since they are also influenced to some extent by the larger airways. Yet, their sensitivity also implies that when no change is observed in these small airway indices, it is highly probable that no changes in the small airways have occurred (taking into account the magnitude of change for which the study is powered with respect to any particular small airway parameter).
Given that in asthma, disease severity appears to be correlated specifically with acinar ventilation heterogeneity [3] , it may be important to target any abnormality of ventilation distribution in the acinar zone at an early stage, before patients develop symptoms. The otherwise stable asthma population under study, with a clear-cut acinar abnormality, was eligible for such targeting as was done here by decreasing particle size. The interpretation of the results in the present study then depends on the clinical angle one wants to adopt. On the one hand, it may be deceiving to observe that small steroid particles were unable to reduce acinar ventilation heterogeneity in these asthma patients. This begs the question of whether this residual small airway dysfunction is irreversible by steroids at all, or whether it is the inhaled route that is ineffective to normalize the most peripheral airway alterations. On the other hand, it is interesting and indeed somewhat surprising, to observe that in patients titrated to low or moderate steroid doses to maintain clinical stability, steroid particle size per se does not appear to matter. When considering equivalence of steroid doses at the basic receptor level, relative potency of budesonide and beclomethasone is 0.75 [16] giving a small potential advantage in favour of the reference medication at the dosages delivered here. Hence, the effect of aerosol formulation and aerosol delivery superimposed upon the receptor potency appears to be such that lung function down to the small airway level is maintained. Since exhaled NO parameters also remained unchanged (Table 2 ) either formulation appears to contain sufficient drug dose to suppress eosinophilic inflammation throughout the lungs. Considering the particle sizes that have been reported for the reference medication [mass median aerodynamic diameter (MMAD) of 2.3 mm at 60 L min À1 ] [17] and for the beclomethasone ultrafine particle formulation (MMAD w1.0 mm with geometric standard deviation around 2.5) [18] , there must be an overlap in the size distribution which contains the portion of drug dose that is critical to therapeutic efficacy. This could imply that the larger particles in the size distribution of the reference medication are redundant, potentially producing local side effects via oropharyngeal deposition [19] ; for BDP-HFA, oropharyngeal deposition is relatively low [20] .
Several studies by other groups have also aimed to reduce structural or functional abnormality in the lung periphery of asthma patients by treatment with small particle steroid formulations, yielding sometimes conflicting results. For instance, computed tomography studies have shown a decrease in air trapping with fine particle HFA-BDP in comparison with chlorofluorocarbon BDP (CFC-BDP), but not in comparison with fluticasone propionate [21, 22] . In a 12 weeks open label study HFA-BDP improved all studied IOS indices, whereas CFC-BDP increased all the indices except R 5 eR 20 (thought to reflect small airways resistance) [23] . After 8 weeks, ciclesonide improved IOS indices of small airway function compared with fluticasone propionate in mild asthma [24] . For an exhaustive overview of studies on small particle aerosols in asthma specifically investigating small airways function, we refer to van den Berge et al. [25] ; for particle sizes involved to Leach et al. [26] . Taken together, previous studies indicate that partial reversibility can be obtained in the small airways, but that the actual effect of inhaled steroid particle size is sometimes difficult to discern, also depending on the outcome measure used.
In the present study, we have deliberately studied the asthma patients post-bronchodilation, and we have isolated the steroid from the LABA in a separate inhaler, to study the effect of steroid particle size alone, all other things being equal. The absence of change in any of the small airway parameters in our study can be set against our previous study [4] where a significant but relatively modest reversibility of acinar heterogeneity (of 20% pre-dilation and 15% post-dilation) was obtained in a group of asthma patients with an average baseline Sacin abnormality which was approximately double that in the patients under study here (the post-dilation baseline value for the study population in [4] would correspond to w230%pred). In that study, the fine particle iCS dose was double that used here in the first 6 weeks when most of the effect was observed, before switching to half the iCS dose. Our recruitment strategy for the present study, requesting only that Sacin was above a certain threshold and limited to patients on less than 800 mg BUD equivalent, resulted in a lower median Sacin in this study of 149%pred (162%predicted in the control arm). It could be argued on basis of the alveolar NO obtained here e not measured in [4] e that the most peripheral inflammatory component was already treated in the patients included in the present study, and that any change in particle size would not affect Sacin. In fact, Scond remained unaffected too, as was expected from our previous study [4] .
We suspect that the residual Sacin abnormality observed in these well controlled asthma patients, constituting more or less 50% of the stable asthma population on less than 800 mg BUD equivalent screened, is in fact a reflection of a non-steroid responsive inflammatory process that remains untreated in the lung periphery. This hypothesis can be brought in line with recent data by McGrath et al. [27] who observed that only 36% of mild-to-moderate asthma patients not treated with an iCS and 17% of patients on iCS have sputum eosinophilia, and that the subgroup with the persistent non-eosinophilic phenotype responds poorly to currently available asthma controller medications in terms of airflow obstruction. In specific relation to the age of the patients participating in our study (average:52years), it is worth mentioning a very recent report of an association between greater% sputum neutrophils and greater acinar ventilation heterogeneity in asthma patients aged >40 years [28] . Also, asthma in older adults has been reported to be characterized more frequently by irreversible airway obstruction [29] .
In conclusion, reversibility of the acinar airway abnormality could not be achieved after a switch to a fine particle ICS formulation in asthma patients with well controlled asthma. We suspect that this acinar abnormality, present at baseline despite good asthma control under iCS treatment, persists under the fine particle iCS because it might not be caused by active eosinophilic inflammation or not be a reversible inflammatory process at all. Alternative treatment strategies targeting the small airways should include characterization of the asthma patient in terms of peripheral airway function and inflammation at baseline, to identify those patients who can benefit from any such treatment at all.
